Skip to main content
Premium Trial:

Request an Annual Quote

Toronto Stock Exchange Reviewing GeneNews' Eligibility for Continued Listing

NEW YORK (GenomeWeb) – Canadian molecular diagnostics company GeneNews announced today that it has received notice that the Toronto Stock Exchange is reviewing its eligibility to remain listed on the TSX. GeneNews has 60 days to show that it is in compliance with the continued listing requirements of the exchange.

In early December, the company announced it was restructuring its operations, in response to financial difficulties at Innovative Diagnostics Laboratory (IDL), its joint venture with Cobalt Healthcare Consultants. The company planned to borrow $400,000 and lay off 16 IDL workers, 30 percent of the staff. It signed a one-year working capital loan agreement with a major shareholder, one of the firm's directors, bearing a 2 percent interest rate, repayable on demand, and secured against the firm's intellectual property.

GeneNews said today that the completion of its restructuring plans may positively affect its ability to demonstrate compliance with the TSX listing requirements. 

The company's stock fell nearly 17 percent to less than C$.03 in morning trading on the TSX.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.